GleamWall
中文EN

PBYI PUMA BIOTECHNOLOGY, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%

Margins

Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%

Returns

ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x

Cash quality & payout

Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$228.37M$230.47M
Cost of revenue$58.16M$64.40M
Gross profit$170.21M$166.06M
R&D expense$62.07M$54.94M
SG&A expense$70.85M$80.16M
Operating income$37.30M$30.97M
Interest expense$6.62M$12.45M
Pretax income$35.78M$24.10M
Income tax$4.67M-$6.18M
Net income$31.11M$30.28M
EBITDA$48.24M$42.49M
EPS (basic)0.620.62
EPS (diluted)0.610.62
Weighted avg. shares (diluted)50.65M49.10M
Balance sheet
Cash & equivalents$29.64M$69.22M
Short-term investments$67.89M$31.75M
Receivables$53.65M$32.01M
Inventory$5.51M$8.72M
Current assets$162.69M$147.66M
PP&E, net$187,000$515,000
Intangibles$41.39M$51.13M
Total assets$216.30M$213.33M
Current liabilities$81.25M$96.11M
Short-term debt$22.52M$45.33M
Long-term debt$0$21.72M
Total debt$22.52M$67.05M
Total liabilities$85.96M$121.21M
Shareholders' equity$130.34M$92.12M
Net debt-$7.11M-$2.17M
Shares outstanding50.41M49.11M
Cash flow statement
Operating cash flow$41.80M$38.92M
Capital expenditure$71,000$56,000
Free cash flow$41.73M$38.86M
Investing cash flow-$36.19M-$20.44M
Financing cash flow-$45.20M-$33.85M
Depreciation & amortization$10.94M$11.52M
Stock-based compensation$6.94M$8.24M

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.